Ureaplasma Urealyticum BY PCR

The Ureaplasma Urealyticum BY PCR test uses polymerase chain reaction to detect genetic material (DNA) from Ureaplasma urealyticum in genital or urine samples. PCR identifies even low amounts of bacterial DNA with high sensitivity and specificity, making it a reliable method to confirm active infection where culture may be less sensitive. This test is important because Ureaplasma can be associated with urethritis, abnormal vaginal discharge, pelvic inflammatory disease, adverse pregnancy outcomes and infertility, and accurate identification helps guide appropriate treatment.

This home-collected test is suitable for sexually active adults with symptoms (discharge, dysuria, pelvic pain), people undergoing infertility or prenatal screening, or anyone with a partner diagnosed with an STI. Samples collected discreetly at home are processed in a UAE-accredited laboratory, providing fast, confidential results that support targeted antibiotic therapy and partner management under a clinician’s guidance.

Results are reported as detected/not detected and may include a semi-quantitative load where available; interpretation should be made by a healthcare professional in Dubai/UAE to consider clinical context and local treatment guidelines. To ensure accuracy, follow pre-collection instructions carefully and disclose recent antibiotic use or other treatments when submitting your sample. If positive, your clinician can advise on appropriate antibiotics and partner notification within UAE healthcare protocols.

• Ureaplasma urealyticum DNA (PCR detection)
• Qualitative result: Detected / Not detected
• Semi-quantitative bacterial load (copies/ml) — if performed

• Unusual or persistent genital discharge
• Painful or burning urination (dysuria)
• Pelvic or lower abdominal pain, suspected PID
• Infertility evaluation or recurrent pregnancy loss
• After exposure to a partner with a diagnosed STI

• High sensitivity and specificity compared with culture-based methods
• Discreet home sample collection with courier pickup in Dubai
• Analysis in UAE‑accredited laboratories for reliable reporting
• Fast, confidential results to support targeted treatment decisions
• Reduces unnecessary antibiotic use by confirming the pathogen

• Accepted samples: first-catch urine or genital swab (vaginal/cervical or urethral as instructed)
• Avoid sexual intercourse, douching, or vaginal medications 24–48 hours before collection
• Avoid systemic antibiotics for at least 2 weeks prior, if clinically safe and as directed by your physician
• Provide accurate patient details and recent medication history; results require follow-up with a UAE healthcare provider for interpretation